Home › Therapeutic areas › Oncology › Lymphoma

Lymphoma (17 companies)

Companies with an active program in Lymphoma.

Ticker Company Therapeutic areas Programs Lead stage Mkt cap Programs
ADCT ADC Therapeutics Oncology 3 Approved $172M 5
ALDX Aldeyra Therapeutics DermatologyOncology+1 1 NDA Submitted $41.9M 5
ALLO Allogene Therapeutics ImmunologyOncology Rare 1 Phase 2 $256M 10
ARVN Arvinas NeurologyOncology Rare 1 Approved $447M 10
AUTL Autolus Therapeutics HematologyImmunology+3 Rare 2 Approved $290M 12
CLRB Cellectar Biosciences Oncology 1 Phase 2 $9.2M 7
CRVS Corvus Pharmaceuticals DermatologyOncology+1 Rare 1 Phase 3 $858M 7
FBIO Fortress Biotech DermatologyHematology+4 Rare 1 Approved $61.4M 16
IBRX ImmunityBio Infectious DiseaseOncology 1 Approved $6.66B 17
IMNM Immunome Oncology Rare 1 NDA Submitted $2.03B 9
KZIA Kazia Therapeutics NeurologyOncology Rare 1 Phase 2 $60.7M 13
LEGN Legend Biotech Oncology Rare 4 Approved $3.12B 17
MRKR Marker Therapeutics Oncology 1 Phase 1 $14.0M 5
NKTR Nektar Therapeutics DermatologyImmunology+2 1 Phase 3 $1.23B 11
NRIX Nurix Therapeutics ImmunologyNeurology+1 3 Phase 3 $1.56B 13
SANA Sana Biotechnology MetabolicOncology 1 Phase 1 $563M 4
XNCR Xencor ImmunologyNeurology+1 Rare 2 Approved $2.59B 28